ClinicalTrials.Veeva

Menu

Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery

K

Konkuk University Medical Center

Status

Completed

Conditions

Mitral Regurgitation
Mitral Stenosis
Tricuspid Regurgitation

Treatments

Drug: hydroxyethyl starch (HES 130/0.6)
Procedure: Acute normovolemic hemodilution (ANH)

Study type

Interventional

Funder types

Other

Identifiers

NCT02502448
KUH1160030

Details and patient eligibility

About

Impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established.

Patients undergoing cardiac surgery employing moderate hypothermic CPB (n=40) are randomly allocated into one of two groups: in Group-ANH(n=20), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C, ANH is not applied.

After weaning from CPB, intergroup differences of INTEM, EXTEM, FIBTEM and APTEM profiles are analyzed.

As a primary outcome, inter-group difference between maxiaml clot firmness of EXTEM will be determined at 10 min after ANH in Group-ANH and that at control.

Full description

Background: Impact of acute normovolemic hemodilution (ANH) using hydroxyethyl starch before initiating cardiopulmonary bypass (CPB) on whole blood viscoelastic profile after CPB has not been well established.

Method: Patients undergoing cardiac surgery employing moderate hypothermic CPB (n=40) are randomly allocated into one of two groups: in Group-ANH(n=20), ANH is applied by using a balanced hydroxyethyl starch (HES 130/0.6); and in Group-C ANH is not applied.

Intergroup differences of INTEM, EXTEM, FIBTEM and APTEM profiles are analyzed. after anesthesia induction (control) and after weaning form CPB and protamine neutralization (after-CPB) in both groups. In Group-ANH, those are determined after ANH (after-ANH).

As a primary outcome, inter-group difference between maxiaml clot firmness of EXTEM is determined at 10 min after ANH in Group-ANH and that at control.

As secondary outcomes, intergroup differences of Hematocrit (Hct), Na+, K+, HCO3-, Ca2+, osmolarity, s-Cr are determined Intergroup difference of data at T2 are performed.

Enrollment

70 patients

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent

Exclusion criteria

  • preoperative renal failure requiring reran replacement therapy
  • preoperative liver disease
  • preoperative low cardiac output (EF < 50%)
  • Preoperative IABP application, Atrial fibrillation, Pacemaker,
  • contraindication for applying TEE
  • intraoperative withdrawal

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

70 participants in 2 patient groups

Control group
No Intervention group
Description:
patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
Acute normovolemic hemodilution group
Active Comparator group
Description:
patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
Treatment:
Procedure: Acute normovolemic hemodilution (ANH)
Drug: hydroxyethyl starch (HES 130/0.6)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems